SCHEMBL6522266

SCHEMBL6522266

O=c1[nH]c2ncccc2c2cc(NCc3ccncc3)ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.55
PARP1 P09874 1/20 0.55
CDC7 O00311 2/20 0.46
DBF4 Q9UBU7 2/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
IP6K1 Q92551 1/20 0.45
PARP14 Q460N5 1/20 0.45
DYRK1A Q13627 1/20 0.44
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 4/20 0.41
GAA P10253 3/20 0.41
MAPT P10636 3/20 0.41
CCNT1 O60563 2/20 0.41
CDK9 P50750 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
PABPC1 P11940 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454371 0.91 AURKA (0.60) AURKAPARP1CDC7DBF4CCNE1
SCHEMBL6516089 0.89 AURKA (0.54) AURKAPARP1CDC7DBF4CCNE1
SCHEMBL6521930 0.88 PARP1 (0.52) AURKAPARP1CDC7DBF4CCNE1
SCHEMBL6519406 0.88 AURKA (0.52) AURKAPARP1CDC7DBF4IP6K1
SCHEMBL6518086 0.86 AURKA (0.60) AURKAPARP1CDC7DBF4CCNE1
SCHEMBL6517391 0.85 AURKA (0.49) AURKAPARP1CDC7DBF4IP6K1
SCHEMBL6522983 0.85 PARP1 (0.49) AURKAPARP1CDC7DBF4IP6K1
SCHEMBL6527186 0.85 MAPT (0.51) AURKAPARP1CDC7CDK2DYRK1A
SCHEMBL6523494 0.83 AURKA (0.50) AURKAPARP1IP6K1CCNT1CDK9
SCHEMBL6517978 0.83 CDC7 (0.52) AURKAPARP1CDC7DBF4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885PARP1 1693/4885CDC7 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.